834 related articles for article (PubMed ID: 33657296)
41. Eyelid primary diffuse large B-cell lymphoma.
Huerva V; Canto LM
Can J Ophthalmol; 2008 Apr; 43(2):240-1. PubMed ID: 18347633
[No Abstract] [Full Text] [Related]
42. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
43. Antibodies for the treatment of diffuse large cell lymphoma.
Blum KA; Bartlett NL
Semin Oncol; 2003 Aug; 30(4):448-56. PubMed ID: 12939713
[TBL] [Abstract][Full Text] [Related]
44. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.
Riihijärvi S; Fiskvik I; Taskinen M; Vajavaara H; Tikkala M; Yri O; Karjalainen-Lindsberg ML; Delabie J; Smeland E; Holte H; Leppä S
Haematologica; 2015 Feb; 100(2):238-45. PubMed ID: 25381134
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation.
Ferrara F; Viola A; Copia C; Schiavone EM; Celentano M; Pollio F; D'Amico MR; Palmieri S
Hematol Oncol; 2006 Jun; 24(2):73-7. PubMed ID: 16550628
[TBL] [Abstract][Full Text] [Related]
46. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Sauter CS; Senechal B; Rivière I; Ni A; Bernal Y; Wang X; Purdon T; Hall M; Singh AN; Szenes VZ; Yoo S; Dogan A; Wang Y; Moskowitz CH; Giralt S; Matasar MJ; Perales MA; Curran KJ; Park J; Sadelain M; Brentjens RJ
Blood; 2019 Aug; 134(7):626-635. PubMed ID: 31262783
[TBL] [Abstract][Full Text] [Related]
47. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
[TBL] [Abstract][Full Text] [Related]
48. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C
Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288
[TBL] [Abstract][Full Text] [Related]
49. Safety of CAR T-cell therapy in kidney transplant recipients.
Mamlouk O; Nair R; Iyer SP; Edwards A; Neelapu SS; Steiner RE; Adkins SA; Hawkins M; Saini N; Devashish K; Strati P; Mandayam S; Ahmed S
Blood; 2021 May; 137(18):2558-2562. PubMed ID: 33512386
[No Abstract] [Full Text] [Related]
50. Anaplastic large cell lymphoma in leukemic transformation: successful treatment by transplantation.
Wu SJ; Yao M; Tien HF; Tang JL; Lin CW; Chen YC
J Clin Oncol; 2007 Oct; 25(28):4490-2. PubMed ID: 17906210
[No Abstract] [Full Text] [Related]
51. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma.
Hahn T; Wolff SN; Czuczman M; Fisher RI; Lazarus HM; McCarthy PL; Vose J; Warren L; Watt R;
Biol Blood Marrow Transplant; 2003 Oct; 9(10):667. PubMed ID: 14569563
[No Abstract] [Full Text] [Related]
52. Diffuse large B-cell lymphoma in immunoprivileged sites: association of vitreoretinal, testicular and central nervous system lymphoma.
Riemens A; Missotten T; Baarsma S; Vidovic-Valentincic N; Novac-Andrejcic K; Erckens R; Kuijpers R; Lokhorst H; Rothova A
Acta Ophthalmol; 2014 Mar; 92(2):e159-60. PubMed ID: 23819861
[No Abstract] [Full Text] [Related]
53. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
Qiao W; Zhao J; Xing Y; Wang C; Wang T
Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
55. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
Zinzani PL; Broccoli A; Stefoni V; Musuraca G; Abruzzese E; De Renzo A; Cantonetti M; Bacci F; Baccarani M; Pileri SA
Cancer; 2010 Dec; 116(24):5667-75. PubMed ID: 20737566
[TBL] [Abstract][Full Text] [Related]
56. "Double-expressor" intravascular large B-cell lymphoma involving the female genital tract.
Alrabeh R; Hao S
Blood; 2018 Jun; 131(26):2993. PubMed ID: 29954821
[No Abstract] [Full Text] [Related]
57. Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation.
Escobar IG; Alonso PT; Barrigon DC; Perez-Simon JA; Mateos Manteca MV; San Miguel Izquierdo JF
Ann Nucl Med; 2008 May; 22(4):251-60. PubMed ID: 18535875
[TBL] [Abstract][Full Text] [Related]
58. Progressive multifocal leukoencephalopathy after CAR T therapy.
Sdrimas K; Diaz-Paez M; Camargo JF; Lekakis LJ
Int J Hematol; 2020 Jul; 112(1):118-121. PubMed ID: 32125605
[TBL] [Abstract][Full Text] [Related]
59. ALK-negative anaplastic lymphoma after autologous stem cell transplant for relapsed diffuse large B-cell lymphoma.
Lim SH; Guileyardo JM; Graham R; Strong LR; Esler WV
Leuk Res; 2011 Jun; 35(6):e59-60. PubMed ID: 21146873
[No Abstract] [Full Text] [Related]
60. Primary B-cell lymphoma of choroid plexus in a 30-year-old immunocompetent male.
Rumana M; Kirmani A; Khursheed N; Naseer S; Rayees M; Khalil MB
Clin Neuropathol; 2011; 30(3):152-4. PubMed ID: 21545777
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
